GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » JBM (Healthcare) Ltd (HKSE:02161) » Definitions » 14-Day RSI

JBM (Healthcare) (HKSE:02161) 14-Day RSI : 76.60 (As of Dec. 13, 2024)


View and export this data going back to 2021. Start your Free Trial

What is JBM (Healthcare) 14-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2024-12-13), JBM (Healthcare)'s 14-Day RSI is 76.60.

The industry rank for JBM (Healthcare)'s 14-Day RSI or its related term are showing as below:

HKSE:02161's 14-Day RSI is ranked worse than
97.72% of 1095 companies
in the Drug Manufacturers industry
Industry Median: 49.56 vs HKSE:02161: 76.60

Competitive Comparison of JBM (Healthcare)'s 14-Day RSI

For the Drug Manufacturers - Specialty & Generic subindustry, JBM (Healthcare)'s 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


JBM (Healthcare)'s 14-Day RSI Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, JBM (Healthcare)'s 14-Day RSI distribution charts can be found below:

* The bar in red indicates where JBM (Healthcare)'s 14-Day RSI falls into.



JBM (Healthcare)  (HKSE:02161) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


JBM (Healthcare)  (HKSE:02161) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


JBM (Healthcare) 14-Day RSI Related Terms

Thank you for viewing the detailed overview of JBM (Healthcare)'s 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


JBM (Healthcare) Business Description

Traded in Other Exchanges
N/A
Address
108 Wai Yip Street, Units 808-811, 8 floor, C-Bons International Centre, Kwun Tong, Kowloon, Hong Kong, HKG
JBM (Healthcare) Ltd markets and distributes healthcare products. The company's operating segment includes Branded medicines; Proprietary Chinese medicines and Health and wellness products. It generates maximum revenue from the Proprietary Chinese medicines segment. The Proprietary Chinese medicines segment develops, manufactures, and distributes registered Chinese medicines composed solely of any Chinese herbal medicines specified in the Chinese Medicine Ordinance, or any materials of herbal, animal, or mineral origin customarily or widely used by the Chinese. Geographically, it derives a majority of its revenue from Hong Kong.
Executives
Ubs Trustees (b.v.i.) Limited
Kingshill Development Group Inc
Sum Kwong Yip, Derek
Queenshill Development Limited
Lincoln's Hill Development Limited
Yun Nan Bai Yao Ji Tuan Gu Fen You Xian Gong Si
New Heritage Healthcare Limited 2101 Beneficial owner
Gavett Limited 2201 Interest of corporation controlled by you
United Islands Group Limited 2201 Interest of corporation controlled by you
Fortstar Limited 2201 Interest of corporation controlled by you
Tao Richard 2201 Interest of corporation controlled by you
Hon Hing Tong Patricia 2202 Interest of your spouse
Tao Paul 2201 Interest of corporation controlled by you
Choi Siu Ping 2202 Interest of your spouse
Longjin Investments Limited 2101 Beneficial owner

JBM (Healthcare) Headlines

No Headlines